Tulavi Therapeutics, a private medical technology company focused on advancing surgical solutions that address critical unmet needs in peripheral nerve surgery and repair, today announced a new partnership with Veterans Healthcare Supply Solutions (VHSS) to distribute the allay™ Hydrogel Cap to U.S. Department of Veterans Affairs (VA) hospitals and Military Treatment Facilities nationwide. This milestone brings Tulavi's innovative technology to the forefront of veteran care and expands access to a new treatment for peripheral nerve injuries while broadening the scope of advanced surgical options for nerve protection and recovery.

More than 60,000 U.S. veterans are living with limb loss, and countless others have sustained traumatic peripheral nerve injuries requiring surgical intervention. In these cases, peripheral nerves are often severed or transected during amputation or surgical soft tissue repair. When a peripheral nerve is injured or cut, regenerating axons may grow erratically, resulting in the development of neuromas that are the leading cause of chronic nerve pain and can significantly impair mobility, prosthetic use, and quality of life.1,2

The allay™ Hydrogel Cap is a novel, fully absorbable, and entirely sutureless medical device that provides a perfectly conforming and protective barrier to the injured nerve, supporting nerve recovery while reducing the risk of neuroma formation. Once deployed, the hydrogel cap remains in place for approximately eight months, protecting the nerve and blocking axonal escape during the critical period of neuroma formation. Its simple surgical application and full resorption over time make it ideally suited for the essential peripheral nerve procedures routinely performed in VA and military settings.

"Our veterans and their families deserve access to technologies that support recovery from life-altering injuries and disabilities," said Josh Vose, MD, CEO of Tulavi. "This partnership with VHSS enables the VA and military surgeons to access the best medical technology available for reducing the risk of neuroma formation, through established procurement pathways, bringing the allay™ Hydrogel Cap directly to those who need it most."

"We're proud to work with Tulavi to make innovative, clinically driven solutions like allay™ available to surgeons at VA hospitals and military treatment centers," said Ryan Hurt, CEO at VHSS. "Improving recovery and reducing the risk of long-term complications for veterans and their families is at the heart of our mission."

 

Source: prnewswire.com

Report Abuse